Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism

First-of-its-kind meeting spotlights IMNN-001 as one of the novel technologies shaping the future of cancer drug discovery and development

LAWRENCEVILLE, N.J., July 23, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that new data on IMNN-001, the Company's DNA-based interleukin-12 (IL-12) immunotherapy for advanced ovarian cancer, will be featured in a poster presentation at the inaugural AACR Conference on Drug Discovery and Development (AACR D3), July 21-24, 2026 in Boston, Massachusetts.

AACR D3 is a new conference from the American Association for Cancer Research designed to bring together scientists, clinicians, biopharma companies and investors around emerging technologies and novel approaches spanning the drug discovery and development continuum, rather than focusing solely on late-stage clinical results. IMUNON's presentation introduces its TheraPlas® platform technology alongside supporting translational and clinical data from its ovarian cancer program.

The standard-of-care treatment for newly diagnosed advanced ovarian cancer has not meaningfully changed in three decades. IMNN-001 is a proprietary novel DNA-based agent that produces therapeutic levels of interleukin-12 (IL-12), a multipotent anti-tumor cytokine, directly to the tumor site. Unlike systemic administration of recombinant IL-12, which is associated with supraphysiological, transient exposure, IMUNON's approach is designed to achieve durable, physiologically relevant local IL-12 production intended to drive sustained anti-tumor immune activity. Administered weekly over a 6-month period, we believe this offers a highly favorable safety and efficacy profile and has the potential to substantially improve therapeutic outcomes.